Tirzepatide is a revolutionary peptide, the first of its class to act as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual synergistic action significantly enhances glycemic control, appetite suppression, and metabolic optimization, often outperforming selective GLP-1 agonists in comparative studies.
Presentation: 5mg / 10mg / 30mg lyophilized vial.
Tirzepatide mimics the action of two natural incretin hormones: GLP-1 and GIP. GLP-1 regulates appetite and caloric intake in the brain, while GIP complements this action by improving insulin secretion and lipid metabolism. By activating both receptors simultaneously, Tirzepatide achieves a "Twincretin" effect that results in superior efficacy in glucose regulation and weight reduction compared to single-receptor agonists.(1)
In extensive clinical trials (such as the SURMOUNT series), Tirzepatide has demonstrated unprecedented results in body weight reduction. Participants have experienced significant weight losses, often exceeding 20% of their initial weight, bringing it close to bariatric surgery results but through pharmacological intervention.(2)
In addition to weight loss, Tirzepatide improves multiple cardiovascular risk markers. A reduction in blood pressure, decrease in triglycerides and LDL cholesterol, and an increase in insulin sensitivity have been observed. This suggests significant long-term cardioprotective potential.(3)
Initially approved for the treatment of Type 2 Diabetes, Tirzepatide has shown superior ability to reduce HbA1c (glycosylated hemoglobin) levels compared to other standard treatments, including basal insulin. Its dual action improves pancreatic beta-cell function and insulin sensitivity.(4)
